# Intranasal Vasopressin Treatment in Children With Autism

> **NCT03204786** · PHASE2,PHASE3 · COMPLETED · sponsor: **Stanford University** · enrollment: 157 (actual)

## Conditions studied

- Autism
- Autism Spectrum Disorder
- ASD

## Interventions

- **DRUG:** Vasopressin (USP) Injectable Solution [Vasostrict]
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03204786
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-20
- **Primary completion:** 2024-03-18
- **Final completion:** 2024-03-18
- **Target enrollment:** 157 (ACTUAL)
- **Last updated:** 2025-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03204786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03204786, "Intranasal Vasopressin Treatment in Children With Autism". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03204786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*